The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
21-gene Recurrence Score testing and subsequent treatment decisions in patients (pts) with estrogen-receptor-positive (ER+) early-stage breast cancer (ESBC).
Jennifer B. Manders
Research Funding - Genomic Health
Joan Burkhart
No relevant relationships to disclose
Debra Campbell
No relevant relationships to disclose
James J. Devitt
No relevant relationships to disclose
Judith Vacchino
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Amy Pratt Sing
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health